WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2006080533) 3-AMINO-1,2,4-TRIAZOLE DERIVATIVE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/080533    International Application No.:    PCT/JP2006/301586
Publication Date: 03.08.2006 International Filing Date: 31.01.2006
A61K 31/4196 (2006.01), A61K 31/422 (2006.01), A61K 31/423 (2006.01), A61K 31/4439 (2006.01), A61K 31/454 (2006.01), A61K 31/4725 (2006.01), A61K 31/5377 (2006.01), A61P 3/06 (2006.01), A61P 3/10 (2006.01), A61P 9/10 (2006.01), A61P 9/12 (2006.01), A61P 19/10 (2006.01), A61P 21/00 (2006.01)
Applicants: MOCHIDA PHARMACEUTICAL CO., LTD. [JP/JP]; 7, Yotsuya 1-chome Shinjuku-ku, Tokyo 1608515 (JP) (For All Designated States Except US).
ITOH, Manabu [JP/JP]; (JP) (For US Only).
OHTA, Masahiko [JP/JP]; (JP) (For US Only).
MIYAZAKI, Yutaka [JP/JP]; (JP) (For US Only)
Inventors: ITOH, Manabu; (JP).
OHTA, Masahiko; (JP).
MIYAZAKI, Yutaka; (JP)
Agent: WATANABE, Mochitoshi; Hayakawa-tonakai Bldg. 3F 12-5, Iwamoto-cho 2-chome Chiyoda-ku, Tokyo 1010032 (JP)
Priority Data:
2005-024618 31.01.2005 JP
2005-112861 08.04.2005 JP
(JA) 3-アミノ-1,2,4-トリアゾール誘導体
Abstract: front page image
(EN)A pharmaceutical composition comprising a 3-amino-1,2,4-triazole derivative represented by the formula (I) or a pharmaceutically acceptable salt or solvate thereof as an active ingredient which is intended to be administered to a patient who is needed for the inhibition of 11&bgr;-HSD1 or the control of 11&bgr;-HSD1 activity. This composition has remarkably improved stability in human serum and is highly promising as a therapeutic agent.
(FR)La présente invention a pour objet une préparation thérapeutique comprenant un dérivé de 3-amino-1,2,4-triazole de formule (I) ou un sel de qualité pharmaceutique ou un solvate dudit dérivé au titre de principe actif, ladite préparation étant destinée à être administrée à un patient nécessitant l'inhibition de 11&bgr;-HSD1 ou la régulation de l'activité de 11&bgr;-HSD1. Ladite préparation présente une stabilité remarquablement améliorée dans le sérum humain par rapport à l’art antérieur et se révèle très prometteuse en tant qu'agent thérapeutique.
(JA) ヒト血清中における安定性が顕著であり、医薬としての高い可能性が期待される、式(I)に示す3-アミノ-1,2,4-トリアゾール誘導体、それらの医薬用許容される塩、またはその溶媒和物を有効成分として含有する、11β-HSD1の阻害もしくは、11β-HSD1の活性の調節が必要な患者に投与される為の医薬組成物を提供する。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)